Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine 2014/2015 Influsplit Tetra (Fluarix Tetra) (GSK2321138A) When Co-administered With Pneumovax 23 in Adults 50 Years of Age and Older

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' Quadrivalent Split Virion Influenza Vaccine 2014/2015 Influsplit Tetra (Fluarix Tetra) (GSK2321138A) When Co-administered With Pneumovax 23 in Adults 50 Years of Age and Older

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs GSK 2321138A (Primary) ; Pneumococcal vaccine conjugate PPV 23
  • Indications Influenza virus infections
  • Focus Registrational; Therapeutic Use
  • Acronyms FLU D-QIV-010 PRI
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 29 May 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 23 Jan 2015 Planned End Date changed from 1 Jun 2015 to 1 May 2015 as reported by ClinicalTrials.gov record.
    • 07 Dec 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top